药明康德
(603259)
| 流通市值：1287.47亿 | | | 总市值：1486.74亿 |
| 流通股本：25.01亿 | | | 总股本：28.88亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 27,702,002,254.76 | 17,240,918,263.02 | 7,981,934,236.96 | 40,340,806,877.04 |
| 营业收入 | 27,702,002,254.76 | 17,240,918,263.02 | 7,981,934,236.96 | 40,340,806,877.04 |
| 二、营业总成本 | 19,967,164,047.62 | 12,203,655,162.93 | 5,643,908,863.64 | 28,708,590,806.38 |
| 营业成本 | 16,440,256,129.17 | 10,453,936,890.44 | 4,938,382,494.26 | 23,728,799,637.77 |
| 税金及附加 | 218,784,249.97 | 146,876,170.27 | 68,532,047.64 | 297,479,375.46 |
| 销售费用 | 546,582,318.74 | 357,521,839.98 | 179,093,852.13 | 701,029,692.54 |
| 管理费用 | 1,869,468,114.84 | 1,212,235,637.14 | 575,859,743.18 | 2,878,770,842.66 |
| 研发费用 | 954,042,826.94 | 636,308,858.78 | 306,402,572.33 | 1,440,630,437.19 |
| 财务费用 | -61,969,592.04 | -603,224,233.68 | -424,361,845.9 | -338,119,179.24 |
| 其中:利息费用 | 150,222,876.33 | 107,053,052.78 | 51,078,664.38 | 139,976,715.73 |
| 其中:利息收入 | 467,311,764.91 | 316,477,649.99 | 161,136,417.95 | 444,470,241.55 |
| 加:公允价值变动收益 | 217,646,546.11 | -99,587,866.93 | -84,011,506.61 | -37,809,127.95 |
| 加:投资收益 | -164,809,637.05 | 22,379,410.5 | -8,925,102.88 | 233,848,997.4 |
| 资产处置收益 | -7,955,695.32 | -3,454,353.96 | -1,485,681.82 | -33,450,046.48 |
| 资产减值损失(新) | -20,104,426.49 | 11,412,652.34 | 6,594,693.15 | -156,508,914.41 |
| 信用减值损失(新) | -155,999,892.45 | -83,107,058.67 | -20,737,646.25 | -238,403,367.77 |
| 其他收益 | 287,254,161.42 | 193,548,192.9 | 80,387,049.85 | 472,392,295.02 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 7,890,869,263.36 | 5,078,454,076.27 | 2,309,847,178.76 | 11,872,285,906.47 |
| 加:营业外收入 | 5,586,936.32 | 4,035,872.06 | 1,664,315.57 | 16,596,329.57 |
| 减:营业外支出 | 42,160,110.47 | 32,936,177.98 | 14,117,354.53 | 56,891,244.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 7,854,296,089.21 | 5,049,553,770.35 | 2,297,394,139.8 | 11,831,990,991.15 |
| 减:所得税费用 | 1,252,684,573.24 | 768,708,087.44 | 338,540,934.85 | 2,131,730,957.88 |
| 六、净利润 | 6,601,611,515.97 | 4,280,845,682.91 | 1,958,853,204.95 | 9,700,260,033.27 |
| 持续经营净利润 | 6,601,611,515.97 | 4,280,845,682.91 | 1,958,853,204.95 | 9,700,260,033.27 |
| 归属于母公司股东的净利润 | 6,532,934,698.28 | 4,239,822,013.11 | 1,942,210,693.65 | 9,606,749,135.07 |
| 少数股东损益 | 68,676,817.69 | 41,023,669.8 | 16,642,511.3 | 93,510,898.2 |
| (一)基本每股收益 | 2.25 | 1.46 | 0.67 | 3.27 |
| (二)稀释每股收益 | 2.24 | 1.45 | 0.66 | 3.24 |
| 八、其他综合收益 | -3,353,834.76 | 14,733,694.61 | -213,721,368.52 | 86,920,855.5 |
| 归属于母公司股东的其他综合收益 | -3,156,713.02 | 17,103,453.09 | -210,365,488.48 | 88,303,227.45 |
| 九、综合收益总额 | 6,598,257,681.21 | 4,295,579,377.52 | 1,745,131,836.43 | 9,787,180,888.77 |
| 归属于母公司股东的综合收益总额 | 6,529,777,985.26 | 4,256,925,466.2 | 1,731,845,205.17 | 9,695,052,362.52 |
| 归属于少数股东的综合收益总额 | 68,479,695.95 | 38,653,911.32 | 13,286,631.26 | 92,128,526.25 |
| 公告日期 | 2024-10-29 | 2024-07-30 | 2024-04-30 | 2024-03-19 |
| 审计意见(境内) | | | | 标准无保留意见 |